Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Sci Rep. 2019 Dec 11;9(1):18866. doi: 10.1038/s41598-019-55319-z.
Overexpression of LAPTM4B-35 (lysosomal-associated transmembrane protein 4β-35) is associated with a poor prognosis in numerous malignant tumours. Expression patterns and effects of LAPTM4B-35 on head and neck squamous cell carcinomas (HNSCC) are unknown. The aim of this study was to investigate the prognostic relevance of LAPTM4B-35 in HNSCC. Tissue microarrays were constructed with primary tumours and associated lymph node metastases isolated from 127 patients. The expression of LAPTM4B-35 was investigated by immunohistochemistry and the results were correlated with survival data. LAPTM4B-35 in the primary tumour was highly expressed in 47.2% of the patients (60/127). LAPTM4B-35 expression was significantly associated with tumour stage. Moreover, overexpression of LAPTM4B-35 correlated with a significantly worse disease-free survival (10.23 years vs. not reached) and a higher recurrence rate (40.7% vs. 25%). High expression of LAPTM4B-35 in lymph node metastasis was found in 29.2% of cases. In 19.4% of cases, high LAPTM4B-35 expression was observed in both the primary tumour and corresponding lymph node metastases. In conclusion, our data indicates that overexpression of LAPTM4B-35 is associated with poor prognosis and may therefore serve as a new prognostic marker in HNSCC.
LAPTM4B-35（溶酶体相关跨膜蛋白 4β-35）的过表达与许多恶性肿瘤的不良预后相关。LAPTM4B-35 在头颈部鳞状细胞癌（HNSCC）中的表达模式和作用尚不清楚。本研究旨在探讨 LAPTM4B-35 在 HNSCC 中的预后相关性。使用 127 例患者的原发肿瘤和相关淋巴结转移体构建组织微阵列。通过免疫组织化学研究 LAPTM4B-35 的表达，并将结果与生存数据相关联。在 127 例患者中，47.2%（60/127）的患者原发肿瘤中 LAPTM4B-35 表达较高。LAPTM4B-35 的表达与肿瘤分期显著相关。此外，LAPTM4B-35 的过表达与无病生存率显著降低（10.23 年 vs. 未达到）和复发率升高相关（40.7% vs. 25%）。在 29.2%的病例中观察到淋巴结转移中 LAPTM4B-35 的高表达。在 19.4%的病例中，在原发肿瘤和相应的淋巴结转移中均观察到 LAPTM4B-35 的高表达。总之，我们的数据表明 LAPTM4B-35 的过表达与不良预后相关，因此可能成为 HNSCC 的新预后标志物。
